Dr Teresa Alonso Gordoa provides a summary of the poster presented at the ENETS 2020 conference: SSAs for pancreatic neuroendocrine tumours: is there any benefit when Ki-67 is ≥10%?

Dr Teresa Alonso Gordoa is a Medical Oncologist at the Medical Oncology Department of the Hospital Universitario Ramón y Cajal in Madrid. She finalized the degree of medicine by the University of Navarre in 2008 and the medical oncology specialization by the Hospital Universitario Clínico San Carlos in 2013. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors and in the early drug development unit. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the European Society for Medical Oncology (ESMO), the Spanish Society of Genitourinary Oncology (SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented communications in national and international congresses and has participated in the publication of scientific articles in national and international journals.

Dr Teresa Alonso Gordoa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer, BMS, Eusa Pharma, Novartis, Roche, Sanofi Genzyme, Ipsen and Pfizer. 

Dr Mauro Cives works as Assistant Professor of Medical Oncology in the Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. He gained his MD degree and specialization degree in Medical Oncology at the University of Bari. From 2013 to 2016 Dr Cives worked as Research Associate within the Neuroendocrine Program of the Moffitt Cancer Center & Research Institute, Tampa (FL, USA). Dr Cives’ work focuses on the preclinical and clinical evaluation of innovative treatments for neuroendocrine tumors (NETs). In 2017, Dr Cives was awarded by the European Neuroendocrine Tumor Society (ENETS) for the project “CAR-T cells for GEP-NETs”. Dr Cives is co-author of over 30 peer-reviewed papers.

Asst. Prof. Mauro Cives has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA and Ipsen. 

Dr Laskaratos is a specialist registrar in gastroenterology and general internal medicine in London, UK. He has an interest in neuroendocrine tumours and is currently a clinical research fellow in the Neuroendocrine Tumour Unit, ENETS Centre of Excellence of the Royal Free Hospital. Dr Laskaratos qualified from the University of Athens in 2008 and was awarded a prize from the Academy of Athens for graduating first in rank out of 250 students. He subsequently completed his early medical training in the London Deanery and entered into gastroenterology specialty training within the North Central/East Thames rotation. Dr Laskaratos also has a special interest in medical education and has been awarded an MSc in education from University College London.

Dr Elettra Merola is a gastroenterologist who is currently working at Santa Chiara Hospital in Trento (Italy). She received her medical degree in 2005 from Campus Bio Medico (Rome, Italy). She completed her residency in Gastroenterology in 2009, and her PhD in Digestive Oncology at Sapienza University (Rome, Italy) in 2013, where she worked until May 2017. She was awarded in March 2017 with the ENETS CoE Academy Fellowship Grant for a cooperative project developed at the FAU Erlangen University (Germany), where she worked with Prof. Pavel until April 2018. She has been visiting researcher in different institutes (Charité University, Germany; University of Illinois at Chicago, Temple University, Philadelphia, USA). She has led several cooperative studies aimed at improving clinical management of patients affected by neuroendocrine tumors, and has been a member of the Knowledge Network.

Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.

Dr Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED. 

 

Dr Rachel van Leeuwaarde is an endocrinologist at the department of Endocrine Oncology at the University Medical Center of Utrecht, The Netherlands. She graduated cum laude from the Vrije University in Amsterdam and completed her Internal Medicine residency at the University Medical Center of Utrecht. During her endocrinology fellowship she developed an interest in endocrine oncology. Currently she is a staff member at the department of Endocrine Oncology at the University Medical Center of Utrecht and the Antoni van Leeuwenhoek hospital in Amsterdam. During her PhD trajectory on Multiple Endocrine Neoplasia Type 1, she completed a master in Epidemiology at the Julius Center for Health Sciences and Primary Care at the University Medical Center of Utrecht. Her PhD study was on “The impact of screening in Multiple Endocrine Neoplasia type 1”. Dr van Leeuwaarde’s research focusses on endocrine tumor syndromes such as Multiple Endocrine Neoplasia type 1 & 2 and Von Hippel Lindau disease with a special interest in screening and the health related quality of life in these syndromes.

Dr Louis de Mestier serves as Assistant Professor in the Department of Pancreatology - Digestive Oncology at the ENETS Centre of Excellence of Beaujon University Hospital in Clichy (Université Paris-Cité), France. He obtained his specialist diplomas in Hepato-Gastroenterology and Digestive Oncology at the University of Reims, France. He has completed a PhD in Cancer Biology at the University of Paris-Cité in 2021. His clinical interests are on neuroendocrine tumors and pancreatic diseases. His main areas of clinical and translational research include tumor heterogeneity, molecular biomarkers and personalized treatment in NETs. He has been member of the Advisory Board of the French Neuroendocrine Tumor Networks (GTE, RENATEN) since 2020, and joined the Advisory Board of the European Neuroendocrine Tumor Society (ENETS) in 2022. He has participated in more than 100 medical publications, including more than 50 indexed papers in the field of NETs.

Asst. Prof. Louis de Mestier has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Novartis, Pfizer, Ipsen. 

Dr Jorge Hernando is a Medical Oncologist at Vall d´Hebron University Hospital in Barelona, Spain. Jorge obtained his MD degree in 2010, and the Specialty in Medical Oncology in 2016 at the Miguel Servet University Hospital in Zaragoza, Spain. In 2017 he obtained his PhD and joined the Gastrointestinal and Endocrine Tumor Unit at Vall d´Hebron University Hospital. He is mainly committed to the clinical management of patients affected by gastrointestinal, neuroendocrine and endocrine malignancies. Jorge is involved in clinical and translational research projects at the Vall d´Hebron Institute of Oncology (VHIO) and he is also coordinator of the gastrointestinal and neuroendorine patient advocacy group. Dr Hernando is involved in professional societies including the American Society of Clinical Oncology (ASCO), European Society for Medical Onology (ESMO), European Neuroendocrine Tumor Society (ENETS) and Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).

Dr Panpan Zhang works as a Medical Oncologist specialized in gastrointestinal carcinomas and neuroendocrine neoplasms (NENs) at the Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, in Beijing, China. She gained her MD degree in Medical Oncology and currently is a PhD student at the Peking University. Her major research interests are neuroendocrine tumors (NETs) and gastrointestinal carcinomas. From 2014, her clinical work and research has focused on the development of innovative treatments for NETs. She has just returned from a short-term fellowship at the Erasmus MC, The Netherlands. She is actively involved in several prospective clinical trials in NETs and gastrointestinal cancers, aimed at achieving a better understanding of these malignancies and improving clinical management of patients. In addition, she is a member of the multidisciplinary team at Beijing Cancer Hospital and the Chinese Neuroendocrine Tumor Society (CNETS).

Programme summary
Watch the video now
Other episodes in this series
SSAs for pancreatic neuroendocrine tumours – ENETS 2020

SSAs for pancreatic neuroendocrine tumours – ENETS 2020

Episode 1: Poster #1 Current Episode
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Ipsen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Ipsen and from Eisai Europe Limited.

Meet the experts

Other programmes of interest

Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Lung cancer expert panel Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.